{"nctId":"NCT01778023","briefTitle":"Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature","startDateStruct":{"date":"2013-01-17","type":"ACTUAL"},"conditions":["Growth Disorder","Idiopathic Short Stature"],"count":54,"armGroups":[{"label":"hGH:12months treatment","type":"EXPERIMENTAL","interventionNames":["Drug: somatropin"]},{"label":"hGH: 6 month un-treatment + 6 month treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: somatropin"]}],"interventions":[{"name":"somatropin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained from subject's parents or legally acceptable representative before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)\n* Pre-pubertal status (males aged from 4 to 11 \\[both inclusive\\], females aged from 4 to 9 \\[both inclusive\\]): an absence of breast development in females (Tanner 1 only) and testicular volume below 4 mL in males\n* Growth hormone level above 10 ng/mL following a stimulation test (test result within 6 months from screening can be used)\n* Height below 3 percentile\n* Bone age below or equal to 12 year\n* Epiphyses confirmed as open in patients at least 10 years or more of age\n\nExclusion Criteria:\n\n* Known presence of one or more pituitary hormone deficiencies (ACTH (adrenocorticotropic hormone), ADH (antidiuretic hormone), FSH (follicle-stimulating hormone), LH (luteinising hormone), TSH (thyroid-stimulating hormone))\n* Known primary hypothyroidism, adrenal insufficiency or hypogonadism (treated or untreated)\n* Specific types of growth failure including, but not limited to, known chromosomal abnormalities associated with growth failure and altered sensitivity to growth hormone\n* Bone age is advanced over chronological age more than 3 years\n* Active malignancy, CNS (central nervous system) trauma, active chemotherapy or radiation therapy for neoplasia\n* Prior history of intracranial hypertension\n* Hypertrophic cardiomyopathy","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Height Velocity (Ht-V)","description":"Height velocity (Ht-V) (cm/year) is the change in height per year (after 6 months of treatment). Ht-V was calculated by Novo Nordisk.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.02","spread":"0.29"},{"groupId":"OG001","value":"6.87","spread":"0.43"}]}]}]},{"type":"SECONDARY","title":"Change in Ht-SDS (Height Standard Deviation Score)","description":"Height standard deviation scores (HSDS) were calculated using Korean growth data (reported by the Korea Centre for Disease Control and Prevention). The mean normal range for HSDS is from -2 to +2. Negative scores below -2 indicate a height below normal range, whereas positive scores above +2 indicate a height above normal.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.04"},{"groupId":"OG001","value":"0.19","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change in IGF Related Factors: IGF-I (Insulin-like Growth Factor-I)","description":"IGF-I (insulin-like growth factor-1) was measured at Visit 1 (screening),Visit 3 (3 months ± 7 days ),Visit 4 (6 months ± 7 days),Visit 5 (9 months ± 7 days ) and Visit 6 (12 months ± 7 days ). Change of IGF-I from baseline to 6 months treatment was calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192.58","spread":"14.00"},{"groupId":"OG001","value":"28.03","spread":"21.81"}]}]}]},{"type":"SECONDARY","title":"Change in IGF Related Factors: IGFBP-3 (Insulin-like Growth Factor Binding Protein-3)","description":"IGFBP-3 was measured at Visit 1(screening), Visit 3 (3 months ± 7 days ), Visit 4 (6 months ± 7 days), 5 (9 months ± 7 days ) and 6 ( 12 months ± 7 days). Change of IGFBP-3 from baseline to 6 months treatment were calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.19"},{"groupId":"OG001","value":"0.22","spread":"0.30"}]}]}]},{"type":"SECONDARY","title":"Change in Bone Age","description":"Change in bone age from the baseline to 6 months.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.2"},{"groupId":"OG001","value":"0.5","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Adverse Events","description":"AEs were collected throughout the trial in both groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Ht-V (Height Velocity)","description":"Height velocity (Ht-V) (cm/year) is the change in height per year (after 6 months of treatment). Three sort of Ht-V was calculated from height data at Visit 2 (day 0), 4 (6 months ± 7 days) and 6 (12 months ± 7 days), as follows: Between Visits 2 and 4, between Visit 4 and 6 and between Visit 2 and 6. Ht-V was calculated by Novo Nordisk. It is the difference between Ht-V for the last 6 months and Ht-V for the first 6 months of treatment. This endpoint was only evaluated for Group A as per the trial protocol.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":36},"commonTop":["Nasopharyngitis","Upper respiratory tract","Influenza","Urticaria","Pyrexia"]}}}